App-Quantinova.ai

Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.

James M. G. Larkin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Cobimetinib

Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis.

Reinhard Dummer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Basal cell carcinoma

Sonidegib

UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma.

Paul D. Nathan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Merkel cell carcinoma

Pazopanib

A rational approach to dose optimisation of pembrolizumab using cost analysis and pharmacokinetic modelling and simulation.

Kayode Ogungbenro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Pembrolizumab

The impact of obesity on outcomes in metastatic melanoma (MM) patients (pts) treated with dabrafenib and trametinib.

Jennifer Leigh McQuade - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Melanoma

Dabrafenib Mesylate

Short-term change in comprehensive geriatric assessment (CGA) scores following treatment of primary breast cancer in older women.

Ruth M. Parks - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Quantifying patients motivations for phase I oncology trials and how expectations change at the first clinical consultation.

Saoirse Olivia Dolly - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Sleep, circadian disruption and neurocognition in breast cancer (BC) patients undergoing chemotherapy.

Michelle Moore - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Recognizing symptom burden in advanced prostate cancer: A global patient and caregiver survey.

William K. Oh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Toxicity and outcome of anti-GD2 Antibody ch14.18/CHO in Front-Line High-Risk Neuroblastoma Patients: Final Results of the Phase III Immunotherapy Randomization (HR-NBL1/SIOPEN Trial).

Ruth Ladenstein - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

ch14.18

Results of the Randomized Intergroup Trial Inter-B-NHL Ritux 2010 for Children and Adolescents with High Risk B-cell Non Hodgkin's Lymphoma and Mature Acute Leukemia: Evaluation of Rituximab Efficacy in Addition to Standard LMB Chemotherapy Regimen

Veronique Minard-Colin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Rituximab

SIOPEL 6: A multi-centre open label randomized phase III trial of the efficacy of Sodium Thiosulphate in reducing ototoxicity in patients receiving cisplatin chemotherapy for standard risk hepatoblastoma.

Penelope Rachel Brock - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hepatoblastoma

sodium thiosulfate

Prognostic factors in stage 4 neuroblastoma treated with busulphan-melphalan: Report from the European HR-NBL1/Siopen trial.

Ruth Ladenstein - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

Melphalan

Phase I dose-escalation and pharmacokinetic (PK) study of regorafenib in pediatric patients with recurrent or refractory solid malignancies.

Birgit Geoerger - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Regorafenib

Second malignancies in patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project.

Mark A. Applebaum - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

N/A

Correlation of killer-cell Ig-like receptor (KIR) haplotypes and Fc-receptor polymorphisms with survival of high-risk relapsed/refractory neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO.

Holger N. Lode - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

ch14.18

Phase 1/2 study of weekly nab-paclitaxel (nab-P) in pediatric patients (pts) with recurrent/refractory solid tumors (STs): dose-finding and pharmacokinetics (PK).

Lucas Moreno - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Paclitaxel

Phase II clinical trial with long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) in patients with high risk neuroblastoma.

Holger N. Lode - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

Interleukin

Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): Results of EURO-EWING 99-R2 randomized trial (EE99R2Loc).

Jeremy Whelan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ewing's sarcoma

Vincristine

Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases: Results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul).

Uta Dirksen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solitary fibrous tumor

Vincristine

Filters

45280 Abstracts